Division of Dermatology and Venereology, Department of Clinical Sciences, Lund University, Lund, SE-22184, Sweden.
Bioinformatics Institute (BII), Agency for Science, Technology and Research (A*STAR), Singapore, 138671, Singapore.
Adv Healthc Mater. 2023 Dec;12(31):e2300987. doi: 10.1002/adhm.202300987. Epub 2023 Sep 21.
Surgical site infections (SSI) are a clinical and economic burden. Suture-associated SSI may develop when bacteria colonize the suture surface and form biofilms that are resistant to antibiotics. Thrombin-derived C-terminal peptide (TCP)-25 is a host defense peptide with a unique dual mode of action that can target both bacteria and the excessive inflammation induced by bacterial products. The peptide demonstrates therapeutic potential in preclinical in vivo wound infection models. In this study, the authors set out to explore whether TCP-25 can provide a new bioactive innate immune feature to hydrophilic polyglactin sutures (Vicryl). Using a combination of biochemical, biophysical, antibacterial, biofilm, and anti-inflammatory assays in vitro, in silico molecular modeling studies, along with experimental infection and inflammation models in mice, a proof-of-concept that TCP-25 can provide Vicryl sutures with a previously undisclosed host defense capacity, that enables targeting of bacteria, biofilms, and the accompanying inflammatory response, is shown.
手术部位感染（SSI）是一种临床和经济负担。当细菌在缝线表面定植并形成对抗生素有耐药性的生物膜时，可能会发生与缝线相关的 SSI。凝血酶衍生的 C 末端肽（TCP）-25 是一种宿主防御肽，具有独特的双重作用模式，可靶向细菌和细菌产物引起的过度炎症。该肽在临床前体内伤口感染模型中显示出治疗潜力。在这项研究中，作者旨在探索 TCP-25 是否可以为亲水聚乳酸缝线（薇乔）提供新的生物活性先天免疫特性。通过体外结合生化、生物物理、抗菌、生物膜和抗炎测定、计算机分子建模研究，以及在小鼠中的实验感染和炎症模型，证明 TCP-25 可以为薇乔缝线提供以前未被发现的宿主防御能力，从而能够靶向细菌、生物膜和伴随的炎症反应。
